Dendritic cell reconstitution is associated with relapse-free survival and acute GVHD severity in children after allogeneic stem cell transplantation.
DCs are potent APCs and key regulators of innate and adaptive immunity. After allo-SCT, their reconstitution in the peripheral blood (PB) to levels similar to those in healthy individuals tends to be slow. We investigate the age- and sex-dependant immune reconstitution of myeloid (mDC) and plasmacytoid DC (pDC) in the PB of 45 children with leukaemia or myelodysplastic syndrome (aged 1-17 years, median 10) after allo-SCT with regard to relapse, acute GVHD (aGVHD) and relapse-free survival. Low pDC/μL PB up to day 60 post SCT are associated with higher incidence of moderate or severe aGVHD (P=0.035), whereas high pDC/μL PB up to day 60 are associated with higher risk of relapse (P<0.001). The time-trend of DCs/μL PB for days 0-200 is a significant predictor of relapse-free survival for both mDCs (P<0.001) and pDCs (P=0.020). Jointly modelling DC reconstitution and complications improves on these simple criteria. Compared with BM, PBSC transplants tend to show slower mDC/pDC reconstitution (P=0.001, 0.031, respectively), but have no direct effect on relapse-free survival. These results suggest an important role for both mDCs and pDCs in the reconstituting immune system. The inclusion of mDCs and pDCs may improve existing models for complication prediction following allo-SCT.
Department of Statistics, University of Warwick, Coventry, UK.
M C
MC
Elze
1] Institute of Cellular Therapeutics, Integrated Research and Treatment Center Transplantation, Hannover Medical School, Hannover, Germany [2] Paediatrics Department, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.
O
O
Ciocarlie
Pediatrics Department, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
A
A
Heinze
Institute of Cellular Therapeutics, Integrated Research and Treatment Center Transplantation, Hannover Medical School, Hannover, Germany.
S
S
Kloess
Institute of Cellular Therapeutics, Integrated Research and Treatment Center Transplantation, Hannover Medical School, Hannover, Germany.
T
T
Gardlowski
Institute of Cellular Therapeutics, Integrated Research and Treatment Center Transplantation, Hannover Medical School, Hannover, Germany.
R
R
Esser
Pediatrics Department, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
T
T
Klingebiel
Pediatrics Department, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
P
P
Bader
Pediatrics Department, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
S
S
Huenecke
Paediatrics Department, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.
M
M
Serban
Institute of Cellular Therapeutics, Integrated Research and Treatment Center Transplantation, Hannover Medical School, Hannover, Germany.
U
U
Köhl
Department of Statistics, University of Warwick, Coventry, UK.
J L
JL
Hutton
D000208:Acute Disease; D000293:Adolescent; D064591:Allografts; D002648:Child; D002675:Child, Preschool; D003713:Dendritic Cells / Q000276:immunology*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000276:immunology / Q000401:mortality; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000401:mortality / Q000628:therapy; D008297:Male; D009190:Myelodysplastic Syndromes / Q000276:immunology / Q000401:mortality / Q000628:therapy; D033581:Stem Cell Transplantation; D015996:Survival Rate